TY - JOUR
T1 - Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis
T2 - Comparison of comprehensive surgical staging and sentinel lymph node algorithm
AU - Multinu, Francesco
AU - Ducie, Jennifer A.
AU - Eriksson, Ane Gerda Zahl
AU - Schlappe, Brooke A.
AU - Cliby, William A.
AU - Glaser, Gretchen E.
AU - Grassi, Tommaso
AU - Keeney, Gary L.
AU - Weaver, Amy L.
AU - Abu-Rustum, Nadeem R.
AU - Leitao, Mario M.
AU - Mariani, Andrea
N1 - Publisher Copyright:
© 2019
PY - 2019/11
Y1 - 2019/11
N2 - Objectives: To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods: Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results: The study included 104 patients (48 LND, 56 SLN). The use of chemoradiotherapy was similar in the 2 cohorts (46% LND vs 50% SLN), but the use of chemotherapy alone (19% vs 36%) or radiotherapy alone (15% vs 2%) differed. Although there was evidence of higher risk of cause-specific death (HR, 2.10; 95% CI, 0.79–5.58; P = 0.14) and lower risk of para-aortic progression (HR, 0.27; 95% CI, 0.05–1.42; P = 0.12) for the LND group, the associations did not meet statistical significance. The risk of progression was not significantly different between the groups (HR, 1.27; 95% CI, 0.60–2.67; P =0.53). In parsimonious multivariable models, high-risk tumor characteristics and nonendometrioid type were independently associated with lower cause-specific survival and progression-free survival. Conclusions: In EC patients with nonbulky positive lymph nodes, use of the SLN algorithm with limited nodal dissection does not compromise survival compared with LND. Aggressive pathologic features of the primary tumor are the strongest determinants of prognosis.
AB - Objectives: To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods: Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results: The study included 104 patients (48 LND, 56 SLN). The use of chemoradiotherapy was similar in the 2 cohorts (46% LND vs 50% SLN), but the use of chemotherapy alone (19% vs 36%) or radiotherapy alone (15% vs 2%) differed. Although there was evidence of higher risk of cause-specific death (HR, 2.10; 95% CI, 0.79–5.58; P = 0.14) and lower risk of para-aortic progression (HR, 0.27; 95% CI, 0.05–1.42; P = 0.12) for the LND group, the associations did not meet statistical significance. The risk of progression was not significantly different between the groups (HR, 1.27; 95% CI, 0.60–2.67; P =0.53). In parsimonious multivariable models, high-risk tumor characteristics and nonendometrioid type were independently associated with lower cause-specific survival and progression-free survival. Conclusions: In EC patients with nonbulky positive lymph nodes, use of the SLN algorithm with limited nodal dissection does not compromise survival compared with LND. Aggressive pathologic features of the primary tumor are the strongest determinants of prognosis.
KW - Comprehensive surgical staging
KW - Endometrial cancer
KW - Positive lymph node
KW - Sentinel lymph node algorithm
KW - Stage IIIC
UR - http://www.scopus.com/inward/record.url?scp=85073031939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073031939&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2019.09.011
DO - 10.1016/j.ygyno.2019.09.011
M3 - Article
C2 - 31604668
AN - SCOPUS:85073031939
SN - 0090-8258
VL - 155
SP - 177
EP - 185
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -